Science

Ciro Franzese: An international multicenter study of stereotactic radiotherapy for renal cell carcinoma

Ciro Franzese/LinkedIn

Feb 8, 2025, 07:34

Ciro Franzese: An international multicenter study of stereotactic radiotherapy for renal cell carcinoma

Ciro Franzese, Associate Professor in Radiation Oncology at Humanitas University, shared on LinkedIn:

“Joining forces against kidney cancer!

Proud to have contributed to an international multicenter study of stereotactic radiotherapy for renal cell carcinoma.

SBRT is confirmed as a valid therapeutic option with:

96% local control at 5 years
Good preservation of renal function
acceptable toxicity profile, with only 1% of events grade ≥ 3

A step forward to offer inoperable patients an effective and non-invasive therapeutic option.”

Results of Stereotactic Body Radiation Therapy for Primary Renal Cell Carcinoma in a Large Multicenter Series

Authors: Ludwige Abancourt, et al.

Ciro Franzese: An international multicenter study of stereotactic radiotherapy for renal cell carcinoma

cancer Ciro Franzese fight against cancer Global awareness Global fight against cancer Large Multicenter Series non-invasive OncoDaily Oncology renal cell carcinoma Stereotactic Radiotherapy

VERITAC-2 Trial Update: Vepdegestrant Meets Primary Endpoint in ESR1-Mutant Breast Cancer

New Paper Alert: HARMONi-2 study of Ivonescimab vs pembrolizumab for PD-L1-positive non-small cell lung cancer

We are thrilled to welcome Dr. Jasmine Kamboj to the OncoDaily Editorial Board!

Oncologist Near Me – Fedro Alessandro Peccatori: Leading Expert in Gynecological Oncology

MATTERHORN trial - FLOT plus durvalumab will become the new standard of care in the preoperative setting for gastroesophageal cancer

Special Coverage